Item 7.01 Regulation FD Disclosure.
As previously disclosed in the Current Report on Form 8-K filed by Surgalign
Holdings, Inc. (the "Company") with the U.S. Securities and Exchange Commission
on October 5, 2021 (the "Prior Form 8-K"), the U.S. District Court for the
Northern District of Illinois (the "Court") previously granted preliminary
approval of the proposed settlements (the "Settlements") of: (a) the
consolidated derivative action captioned In re RTI Surgical Derivative
Litigation, Lead Case No. 1:20-cv-3347-MFK (the "Derivative Action"); and
(b) the securities class action captioned Lowry v. RTI Surgical Holdings, Inc.,
et al., Case No. 1:20-cv-1939-MFK (the "Class Action"). On January 24, 2022, the
Court granted final approval of the settlement of the Derivative Action. On
January 26, 2022, the Court granted final approval of the settlement of the
Class Action. As part of the Settlements, the Court awarded attorney's fees and
expenses to plaintiffs' counsel, which will be paid by the Company's insurers.
Additional information concerning the Settlements can be found in the Prior Form
8-K and on the "Investor Overview" page of the "Investors" section of the
Company's website, http://ir.surgalign.com. Other information contained in or
accessible through the Company's website does not constitute part of, and is not
incorporated into, this Current Report on Form 8-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
SURGALIGN HOLDINGS, INC. 
